Pivotal Study to Assess the Efficacy, Safety and Tolerability of Dupilumab in Patients With Moderate-to-severe COPD With Type 2 Inflammation

Completed · Phase 3 · Has a placebo group

Conditions studied: Chronic Obstructive Pulmonary Disease

In brief

Primary Objective: To evaluate the efficacy of dupilumab administered every 2 weeks in patients with moderate-or severe Chronic Obstructive Pulmonary Disease (COPD) as measured by * Annualized rate of acute moderate and severe COPD exacerbation (AECOPD) Secondary Objectives: To evaluate the effect of dupilumab administered every 2 weeks on * Pre-bronchodilator forced expiratory volume in 1 second (FEV1) over 12 weeks compared to placebo * Health related quality of life, assessed by the change from baseline to Week 52 in the St. George's Respiratory Questionnaire (SGRQ) * Pre-bronchodilator FEV1 over 52 weeks compared to placebo * Lung function assessments * Moderate and severe COPD exacerbations * To evaluate safety and tolerability * To evaluate dupilumab systemic exposure and incidence of anti-drug antibodies (ADA)

Key facts

Study ID: NCT03930732
Run by: Sanofi
People needed: 939
Starts: 2019-04-15
Expected to finish: 2023-05-02
Last updated by the study team: 2024-02-28

Who can join

Age: 40 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Participants with a physician diagnosis of COPD who met the following criteria at screening:
Current or former smokers with a smoking history of ≥10 pack-years.
Moderate-to-severe COPD (post-bronchodilator FEV1/ forced vital capacity [FVC] ratio <0.70 and post-bronchodilator FEV1 % predicted >30% and ≤70%).
Medical Research Council (MRC) Dyspnea Scale grade ≥2.
Patient-reported history of signs and symptoms of chronic bronchitis (chronic productive cough) for 3 months in the year up to screening in the absence of other known causes of chronic cough.
Documented history of high exacerbation risk defined as exacerbation history of ≥2 moderate or ≥1 severe within the year prior to inclusion. At least one exacerbation should have occurred while the patient was taking inhaled corticosteroid (ICS)/long acting beta agonist (LABA)/long acting muscarinic antagonist (LAMA) (or LABA/LAMA if ICS is contraindicated). Moderate exacerbations were recorded by the investigator and defined as acute exacerbation of COPD (AECOPD) that required either systemic corticosteroids (intramuscular, intravenous, or oral) and/or antibiotics. One of the two required moderate exacerbations had to require the use of systemic corticosteroids. Severe exacerbations were recorded by the investigator and defined as AECOPD requiring hospitalization or observation >24 hours in emergency department/urgent care facility.
Background triple therapy (ICS + LABA + LAMA) for 3 months prior to randomization with a stable dose of medication for ≥1 month prior to Visit 1; Double therapy (LABA + LAMA) allowed if ICS was contraindicated.
Evidence of Type 2 inflammation: Patients with blood eosinophils ≥300 cells/microliter at Visit 1.

You may not qualify if…

COPD diagnosis for less than 12 months prior to randomization.
A current diagnosis of asthma or history of asthma according to the 2018 Global Initiative for Asthma (GINA) guidelines or other accepted guidelines.
Significant pulmonary disease other than COPD (e.g., lung fibrosis, sarcoidosis, interstitial lung disease, pulmonary hypertension, bronchiectasis, Churg-Strauss Syndrome etc) or another diagnosed pulmonary or systemic disease associated with elevated peripheral eosinophil counts.
Cor pulmonale, evidence of right cardiac failure.
Treatment with oxygen of more than 12 hours per day.
Hypercapnia requiring Bi-level ventilation.
AECOPD as defined in inclusion criteria within 4 weeks prior to screening, or during the screening period.
Respiratory tract infection within 4 weeks prior to screening, or during the screening period.
History of, or planned pneumonectomy or lung volume reduction surgery. Patients who were participating in the acute phase of a pulmonary rehabilitation program, ie, who started rehabilitation <4 weeks prior to screening (Note: patients in the maintenance phase of a rehabilitation program could be included).
Diagnosis of α-1 anti-trypsin deficiency.
The above information was not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Where it is running

Clinical Research Center of Alabama, LLC-Site Number:8400041 — Birmingham, Alabama, United States
UAB Lung Health Center-Site Number:8400013 — Birmingham, Alabama, United States
SEC Clinical Research, LLC-Site Number:8400059 — Dothan, Alabama, United States
Pulmonary Associates of Mobile, P.C.-Site Number:8400057 — Mobile, Alabama, United States
Asthma and Allergy Associates, PC-Site Number:8400034 — Colorado Springs, Colorado, United States
Clinical Research Of West Florida Inc-Site Number:8400010 — Clearwater, Florida, United States
Finlay Medical Research-Site Number:8400014 — Greenacres City, Florida, United States
Project 4 research, Inc.-Site Number:8400023 — Miami, Florida, United States
Finlay Medical Research-Site Number:8400062 — Miami, Florida, United States
Renstar Medical Research-Site Number:8400051 — Ocala, Florida, United States
Florida Institute for Clinical Research, LLC-Site Number:8400029 — Orlando, Florida, United States
Emerald Coast Research Associates-Site Number:8400032 — Panama City, Florida, United States
Sarasota Clinical Research-Site Number:8400026 — Sarasota, Florida, United States
VitaLink research-Hamilton Mill-Site Number:8400055 — Dacula, Georgia, United States
DC Research Works-Site Number:8400016 — Marietta, Georgia, United States
North Georgia Clinical Research-Site Number:8400025 — Woodstock, Georgia, United States
Johns Hopkins University (Asthma and Allergy Center)-Site Number:8400012 — Baltimore, Maryland, United States
Asthma Allergy & Sinus Center-Site Number:8400038 — White Marsh, Maryland, United States
Michigan Medicine (University of Michigan)-Site Number:8400050 — Ann Arbor, Michigan, United States
Mayo Clinic Lanmark Center 2-46-Site Number:8400065 — Rochester, Minnesota, United States
Midwest Chest Consultants, P.C.-Site Number:8400011 — Saint Charles, Missouri, United States
Washington University School of Medicine-Site Number:8400004 — St Louis, Missouri, United States
Sierra Clinical Research-Site Number:8400035 — Las Vegas, Nevada, United States
Va Western New York Healthcare-Site Number:8400067 — Buffalo, New York, United States
SEC Clinical Research, LLC-Site Number:8400030 — Andalusia, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.